Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on Oric Pharmaceuticals (ORIC – Research Report). The associated price target remains the same with $17.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Soumit Roy has given his Buy rating due to a combination of factors that highlight ORIC Pharmaceuticals’ potential for growth and success. One of the main reasons is the upcoming data updates from their Phase 1 study, which are expected to provide significant insights into the efficacy and safety of their drug ‘944 in combination with other treatments for prostate cancer. This presents a buying opportunity ahead of these data releases.
Additionally, ORIC’s safety profile is notably better than that of Pfizer’s, which could give it a competitive edge if it maintains this advantage in larger studies. Despite some investor concerns about immature data, the potential for ORIC to match Pfizer’s efficacy while surpassing it in safety is promising. Furthermore, ORIC’s EGFR ex20 NSCLC program is being overlooked by investors, but positive data expected in late 2025 could significantly boost its market potential, with projected peak sales exceeding $500 million in the relapse/refractory setting.
In another report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $12.00 price target.